Andreas Hochheimer, PhD
Scientific Advisor
Drug Discovery & HTS Advisor

Chief Scientific Officer (CSO) at Innoplexus AG, Germany.  In his current role as CSO of Innoplexus, Andreas leverages Artificial Intelligence (AI) and Machine Learning (ML) to translate scientific knowledge into novel therapies to tackle so far incurable diseases and transform drug discovery and development from pipeline to market.  He has more than 25 years professional experience in corporate leadership functions in Biotech & Pharma at Innoplexus AG, Amgen, ISAR Bioscience GmbH and BRAIN AG and as faculty member and researcher at internationally distinguished R&D institutions. Andreas was co-founder and Chief Technology Officer (CTO) of ISAR Bioscience GmbH where he built a translational R&D organization to commercialize next-generation iPSC-derived disease models for drug discovery and regenerative medicine. As Principal Scientist at Amgen in Regensburg, Germany, Andreas enabled the small molecule drug discovery pipeline of Amgen in diverse therapeutic areas including oncology, cardiology, metabolic & inflammatory diseases as well as neurodegeneration. As a leader of Amgen's High-Throughput-Screening (HTS) site in Germany, his group ran the largest target-based HTS campaign for TMEM16A inhibitors to date, identifying niclosamide as one of the most potent inhibitors amongst ~590,000 compounds screened (Frontiers in Pharmacology, Feb. 2019, doi.org/10.3389/fphar.2019.00051).

Andreas obtained a Diploma in Biology and a Ph.D in Microbiology from Philipps-University/Max-Planck-Institute for terrestrial Microbiology Marburg, was Professor in Biochemistry at LMU Munich and served as faculty lecturer in Molecular Cell Biology at TU Darmstadt and University Regensburg.